Prenatal polycyclic aromatic hydrocarbon exposure and asthma at age 8-9 years in a multi-site longitudinal study

Allison R Sherris1, Christine T Loftus1, Adam A Szpiro1

  • 1University of Washington.

Research Square
|July 28, 2023
PubMed

Insights

Prenatal exposure to polycyclic aromatic hydrocarbons (PAHs) showed limited links to childhood asthma. Some adverse effects were noted for girls, but overall evidence was not strong in this large study.

Area of Science:

  • Environmental Health
  • Pediatric Asthma Research
  • Toxicology

Background:

  • Prenatal exposure to polycyclic aromatic hydrocarbons (PAHs) is linked to early childhood wheeze.
  • The impact of prenatal PAH exposure on asthma and wheeze in middle childhood remains unclear.
  • This study investigates these associations in a diverse multi-cohort consortium.

Approach:

  • Analyzed 1,081 parent-child dyads, measuring maternal urinary mono-hydroxylated PAH metabolites (OH-PAH) during pregnancy.
  • Assessed asthma and wheezing trajectories up to age 8-9 years using caregiver reports.
  • Employed regression models, adjusting for multiple covariates, and explored sex-based effect modification and mixture effects.

Key Points:

  • Limited evidence of adverse associations between prenatal OH-PAH concentrations and asthma or wheezing trajectories.
  • Observed adverse associations between 1/9-hydroxyphenanthrene and asthma/persistent wheeze specifically among girls.
  • Found inverse associations with asthma for 1-hydroxynaphthalene, stronger in boys, though not statistically significant for effect modification.

Conclusions:

  • No strong evidence linking prenatal PAH exposure to asthma at age 8-9 years in a large, multi-site cohort.
  • Some sex-specific adverse associations were observed, particularly for girls.
  • Further research may be needed to clarify nuanced relationships and potential sex differences.
Abstract

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
447
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.5K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
365
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K